Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.
Canine inflammatory mammary carcinoma (IMC) is a rare, locally aggressive, highly metastatic tumor that is poorly responsive to treatment. The purposes of this study were to retrospectively evaluate the history, signalment, and clinical signs of dogs with IMC; compare the outcome of affected dogs treated with traditional chemotherapy with those treated with piroxicam; evaluate Cox-2 expression of IMC cells; and correlate Cox-2 expression with outcome based on treatment. Strong cyclooxygenase-2 expression was present in all tumors. Improvement in clinical condition and disease stability was achieved in all dogs treated with piroxicam, with mean and median progression-free survival of 171 and 183 days, respectively. Median survival time of 3 dogs treated with doxorubicin-based protocols was 7 days, which was significantly less than that of dogs treated with piroxicam (median, 185 days). In conclusion, piroxicam should be considered as a single agent for the treatment of dogs with inflammatory mammary carcinoma.
Instituto Nacional de Proteção Animal-INPA, Rua Santa Clara 327A, Copacabana, Rio de Janeiro, Brazil. souzac@missouri.edu
Carlos H
CH
de M Souza
Evandro
E
Toledo-Piza
Renee
R
Amorin
Andrigo
A
Barboza
Karen M
KM
Tobias
D000818:Animals; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology / Q000662:veterinary*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D018450:Disease Progression; D004283:Dog Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D004285:Dogs; D005260:Female; D015870:Gene Expression; D007150:Immunohistochemistry / Q000662:veterinary; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009367:Neoplasm Staging / Q000662:veterinary; D010894:Piroxicam / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D010894:Piroxicam; D051546:Cyclooxygenase 2